Donaghy Anthony
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales 2050, Australia.
J Gastroenterol Hepatol. 2002 Apr;17(4):462-6. doi: 10.1046/j.1440-1746.2002.02761.x.
Malnutrition is a frequent complication of cirrhosis, and many studies have demonstrated the adverse influence of malnutrition on clinical outcomes in patients with cirrhosis. The coexisting complications of fluid overload and ascites may mask the severity of malnutrition, particularly in the early stages of its development. During periods of decompensation, protein and energy requirements are higher, and many patients have inadequate nutritional intake at these times. Further, protein supplementation should not be restricted ad hoc in cirrhotic patients, as for the vast majority of patients dietary protein does not precipitate hepatic encephalopathy. The impairment of hepatic glycogen storage in cirrhotic patients effects a state of accelerated starvation with catabolism of fat and protein to provide substrates for gluconeogenesis. Recent studies have demonstrated the efficacy of nocturnal nutritional supplements in improving nitrogen balance. Resistance to the actions of the anabolic growth factors insulin and growth hormone (GH) is common in cirrhosis, and recent studies have shown that GH resistance, in particular, may be overcome with exogenous GH therapy. Hypermetabolism may be observed in up to one-third of cirrhotic patients. The recent exciting observation that beta-blocker therapy can decrease energy expenditure and catecholamine levels in these patients indicates the need for further intervention studies of beta-blockers as metabolic therapy in cirrhosis.
营养不良是肝硬化常见的并发症,许多研究已证实营养不良对肝硬化患者临床结局有不良影响。液体超负荷和腹水等并存并发症可能掩盖营养不良的严重程度,尤其是在其发展的早期阶段。在失代偿期,蛋白质和能量需求更高,而许多患者此时营养摄入不足。此外,肝硬化患者不应随意限制蛋白质补充,因为绝大多数患者饮食中的蛋白质不会诱发肝性脑病。肝硬化患者肝糖原储存受损导致一种加速饥饿的状态,脂肪和蛋白质分解代谢以提供糖异生的底物。最近的研究表明夜间营养补充剂在改善氮平衡方面的有效性。肝硬化患者中对合成代谢生长因子胰岛素和生长激素(GH)作用的抵抗很常见,最近的研究表明,特别是GH抵抗可以通过外源性GH治疗来克服。高达三分之一的肝硬化患者可能出现高代谢。最近一项令人兴奋的观察结果表明,β受体阻滞剂治疗可降低这些患者的能量消耗和儿茶酚胺水平,这表明有必要进一步开展β受体阻滞剂作为肝硬化代谢治疗的干预研究。